Science Explorer Interactive view Map
Company · Cornellà de Llobregat · Spain

Oryzon Genomics (Spain)

oryzon.comROR OpenAlex
Research works
49
▲ 156% vs 2013–17
Citations
908
18.5 per fractional work
Top-10% rate
22.7%
record average 16.5%
Open access
65%
world 28%

Not ranked overall: Oryzon Genomics (Spain) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.31× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 6.18× its world share, 8 worksBiochemistry, Geneti…Immunology and Microbiology: 1.18× its world share, 0 worksImmunology and Micro…Neuroscience: 1.95× its world share, 1 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 1.77× its world share, 0 worksPharmacology, Toxico…Chemistry: 0.10× its world share, 0 worksChemistryComputer Science: 0.03× its world share, 0 worksComputer ScienceEngineering: 0.02× its world share, 0 worksEngineeringMedicine: 3.08× its world share, 13 worksMedicinePsychology: 0.23× its world share, 0 worksPsychology1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 6.2×. Every wedge is a field page.

Who are the top researchers at Oryzon Genomics (Spain)?

Ranked on the composite score, Tamara Maes lead among researchers whose main affiliation is Oryzon Genomics (Spain).

  1. 1 Tamara Maes Spain · #854,565 worldwide 51 citations · 16 works
All ranked researchers at Oryzon Genomics (Spain)

Which keywords describe research at Oryzon Genomics (Spain)?

By fractional works in 2022–2025, weighted toward what it does more of than the world: Breast Cancer, Chemotherapy, Gene Expression, Metastatic, Monoclonal Antibody, HER2, Trastuzumab and Survival Analysis.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 29 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 29 words, with their numbers
  1. Breast Cancer4▲ 79×5 topics
  2. Chemotherapy4▲ 23×5 topics
  3. Gene Expression3▲ 22×8 topics
  4. Metastatic3▲ 201×2 topics
  5. Monoclonal Antibody3▲ 239×2 topics
  6. HER23▲ 431×1 topic
  7. Trastuzumab3▲ 271×1 topic
  8. Survival Analysis2▲ 37×2 topics
  9. Neoadjuvant Therapy2▲ 40×2 topics
  10. Breast Tumours2▲ 187×1 topic
  11. Molecular Subtypes2▲ 107×2 topics
  12. Prognostic Markers2▲ 83×2 topics
  13. Treatment Response2▲ 187×1 topic
  14. Metastatic Breast Cancer2▲ 135×2 topics
  15. Prognostic Factors2▲ 16×4 topics
  16. Transcriptional Regulation2▲ 40×6 topics
  17. CFTR1▲ 205×1 topic
  18. Cystic Fibrosis1▲ 84×1 topic
  19. Stem Cells1▲ 22×3 topics
  20. Cancer Therapy1▲ 9.4×7 topics
  21. Epidermal Niche1▲ 290×1 topic
  22. Hair Follicle1▲ 290×1 topic
  23. Immunotherapy1▲ 7.3×6 topics
  24. Targeted Therapy1▲ 24×4 topics
  25. Wnt Signaling1▲ 54×2 topics
  26. CDK4/6 Inhibitors1▲ 199×1 topic
  27. Palbociclib1▲ 199×1 topic
  28. Tumor Microenvironment1▲ 11×6 topics
  29. Genetic Mutations1▲ 10×6 topics

Which research topics does Oryzon Genomics (Spain) publish most on?

By volume in 2022–2025: HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Cystic Fibrosis Research Advances and Hair Growth and Disorders.

HER2/EGFR in Cancer Rese…3HER2/EGFR in Cancer Research: 3 fractional worksBreast Cancer Treatment Studies: 2 fractional worksCystic Fibrosis Research Advances: 1 fractional worksHair Growth and Disorders: 1 fractional worksAdvanced Breast Cancer Therapies: 1 fractional worksAcute Myeloid Leukemia R…1Acute Myeloid Leukemia Research: 1 fractional worksProtein Degradation and Inhibitors: 1 fractional worksHistone Deacetylase Inhibitors Research: 1 fractional worksEpigenetics and DNA Methylation: 1 fractional worksLung Cancer Research Studies: 1 fractional works
OncologyCancer ResearchPulmonary and Respiratory MedicineUrology2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 HER2/EGFR in Cancer Research Oncology 3 works
  2. 2 Breast Cancer Treatment Studies Cancer Research 2 works
  3. 3 Cystic Fibrosis Research Advances Pulmonary and Respiratory Medicine 1 works
  4. 4 Hair Growth and Disorders Urology 1 works
  5. 5 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
  6. 6 Acute Myeloid Leukemia Research Hematology 1 works
  7. 7 Protein Degradation and Inhibitors Molecular Biology 1 works
  8. 8 Histone Deacetylase Inhibitors Research Molecular Biology 1 works
  9. 9 Epigenetics and DNA Methylation Molecular Biology 1 works
  10. 10 Lung Cancer Research Studies Oncology 1 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available65.2%not open34.8%

World: 28% of research is openly available.

with international co-authors57.9%domestic only42.1%

World: 19% is written across borders.

How has Oryzon Genomics (Spain)'s research output changed?

Output in 2018–2022 was 156% higher than in 2013–2017.

2005201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Cornellà de Llobregat

All research institutions in Cornellà de Llobregat

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.